Viewing Study NCT05530057


Ignite Creation Date: 2025-12-24 @ 6:42 PM
Ignite Modification Date: 2026-02-17 @ 7:35 PM
Study NCT ID: NCT05530057
Status: RECRUITING
Last Update Posted: 2025-11-20
First Post: 2022-09-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Sponsor: Seoul National University Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module